BioNexus Gene Lab Corp. filings document material-event disclosures for its precision diagnostics strategy, subsidiary governance, capital structure, and periodic reporting obligations. Recent 8-K filings cover VitaGuard™ MRD commercialization activity, the Fidelion Diagnostics relationship, Chemrex governance restructuring, strategic partnership disclosures, and exhibits tied to company press releases and material agreements.
The company’s filing record also includes Form 12b-25 notifications for delayed periodic reports, with explanations tied to financial-reporting transitions and enhanced transaction review. Capital-structure disclosures include registration and equity financing arrangements, while governance disclosures address parent-level oversight, subsidiary board accountability, reporting protocols, and reporting-control processes.
BioNexus Gene Lab Corp reported that its Chief Executive Officer, President and director, Su‑Leng Tan Lee, beneficially owns 338,709 shares of Common Stock, representing approximately 11.5% of the outstanding shares as of August 13, 2026. These shares were granted on August 13, 2026 as a fully vested Other Stock-Based Award under the company’s 2025 Equity Incentive Plan as compensation for completed services, with no cash consideration and source-of-funds code “OO”. For plan valuation purposes only, the company used a fair-market value of $1.55 per share, corresponding to a total plan value of $524,998.95. Tan Lee holds sole voting and dispositive power over all 338,709 shares. The award was issued in an offshore transaction relying on Regulation S, includes a six‑month resale compliance period and related transfer restrictions, and does not obligate the company to register the shares for resale.
Tan Lee Su-Leng reported acquisition or exercise transactions in this Form 4 filing.
BioNexus Gene Lab Corp reported that Chief Executive Officer and director Tan Lee Su-Leng, a more than 10% shareholder, received a fully vested stock award. The award consists of 338,709 common shares with no par value, granted on August 13, 2026 under the company’s 2025 Equity Incentive Plan.
The shares were granted for completed services, with no cash consideration, and were valued for plan purposes at $1.55 per share, based on the Nasdaq closing price on August 12, 2026. Following this grant, the reporting person directly holds 338,709 common shares.
Yap Chee Keong reported acquisition or exercise transactions in this Form 4 filing.
BioNexus Gene Lab Corp director Yap Chee Keong received a fully vested stock award of 32,258 Common Shares on August 13, 2026. The award was granted for completed services under the 2025 Equity Incentive Plan, for no cash consideration, and is held as a direct ownership position of 32,258 shares. For plan purposes, the award was valued at $1.55 per share, equal to the Nasdaq closing price on August 12, 2026.
Bin Abdul Hamid Muhammad Azrul reported acquisition or exercise transactions in this Form 4 filing.
BioNexus Gene Lab Corp director Bin Abdul Hamid Muhammad Azrul received a fully vested stock award of 32,258 Common Shares on August 13, 2026. The award was granted under the company’s 2025 Equity Incentive Plan for completed services, for no cash consideration, and was valued for plan purposes at $1.55 per share, the Nasdaq closing price on August 12, 2026. Following this grant, his direct holdings total 32,258 shares.
Chong Set Fui reported acquisition or exercise transactions in this Form 4 filing.
BioNexus Gene Lab Corp’s Chief Financial Officer, Chong Set Fui, received a fully vested stock-based award of 96,774 common shares on August 13, 2026. The award was granted under the company’s 2025 Equity Incentive Plan for completed services, with no cash consideration, and was valued for plan purposes at $1.55 per share, the Nasdaq closing price on August 12, 2026. Following this grant, Chong Set Fui directly holds 96,774 common shares.
Low Jook Yuen reported acquisition or exercise transactions in this Form 4 filing.
BioNexus Gene Lab Corp director Low Jook Yuen received an equity compensation grant of 16,129 shares of common stock on August 13, 2026. The fully vested Other Stock-Based Award was granted for completed services under the company’s 2025 Equity Incentive Plan, for no cash consideration, and valued for plan purposes at $1.55 per share, the Nasdaq closing price on August 12, 2026. Following this award, Low Jook Yuen holds 17,390 shares of BioNexus Gene Lab Corp common stock directly.
BioNexus Gene Lab Corp. reported sharply lower activity for the six months ended June 30, 2026. Revenue fell to $98,998 from $4,397,328 a year earlier, almost entirely from its industrial chemicals segment, with genomic screening services contributing only $1,961. Gross profit was $12,192 and the company recorded a net loss of $830,026, improved from a loss of $1,239,499 in the prior-year period, helped by $178,691 of other income and tighter operating spending.
Total assets were $8,726,423, including cash and cash equivalents of $2,391,945 and investments in equity securities of $2,026,543. Current liabilities were $812,938, leaving positive working capital, and stockholders’ equity was $7,778,442. However, the company disclosed a substantial doubt about its ability to continue as a going concern, citing the cumulative deficit of $7,257,253, the $830,026 net loss, and $570,162 of operating cash outflows. Management believes existing cash and positive working capital can fund operations for at least twelve months, while noting it may seek additional financing that could include dilutive equity issuance or restrictive debt.
FIDELION DIAGNOSTICS PTE. LTD. is identified as a greater than 5% holder of BioNexus Gene Lab Corp and reports direct ownership of 392,329 shares of common stock. This Form 3 serves as an initial statement of holdings and does not report any specific purchase or sale transactions.
BioNexus Gene Lab Corp disclosed that CEO and director Tan Lee Su-Leng filed a Form 3 reporting her holdings of company equity securities. The report lists 0.0000 shares held directly following a holdings entry dated 2023-08-15, with no buy or sell transactions shown.
BioNexus Gene Lab Corp director Bin Abdul Hamid Muhammad Azrul reports direct ownership of 0 shares of common stock as of 2023-12-11. The entry is presented as a holding record, with no purchase, sale, or derivative transactions reported.